Development of targeted therapies in advanced gastric cancer: Promising exploratory steps in a new era

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 381-385

  Wagner, Anna D ^a   Moehler, Markus ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bevacizumab; Cetuximab; Gastric cancer; Multityrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CATUMAXOMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; MATUZUMAB; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADD ON THERAPY; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ASCITES; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; GENE EXPRESSION; GENE MUTATION; HUMAN; LETHARGY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH PERFORATION; STOMACH TUMOR; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 67650318738     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832c42e0     Document Type: Review

References (31)

1. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008; 68:299-317.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64:31 -49.
3. Cervantes A, Rodriguez Braun E, Perez Fidalgo A, Chirivella Gonzalez I. Molecular biology of gastric cancer. Clin Transl Oncol 2007; 9:208-215.
4. Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity [abstract #11]. In: American Society of Clinical Oncology GI Cancer Symposium 2008; 25-27 January 2008; San Francisco, Alexandria: American Society of Clinical Oncology; 2008.
5. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24:4922-4927.
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
8. Tokunaga A, Onda M, OkudaT, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75:1418-1425.
9. Drescher D, Moehler M, Gockel I, et al. Coexpression of receptor-tyrosine- kinases in gastric adenocarcinoma: a rationale for a molecular targeting strategy? World J Gastroenterol 2007; 13:3605-3609.
10. Tabernero J, MacarullaT, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005; 16:1740-1748.
11. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13:5869-5875.
12. Lordick F, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract #4526]. In: American Society of Clinical Oncology Annual Meeting 2007; 1 -5 June 2007; Chicago, Alexandria: American Society of Clinical Oncology; 2007.
13. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009; 100:298-304.
14. Kim C, Lee J, Ryu M, et al. A prospective phase II study of cetuximab in combination with capecitabine and oxaliplatin (XELOX) in patients with metastatic and/or recurrent advanced gastric cancer [abstract #89]. In: American Society of Clinical Oncology GI Cancer Symposium 2009; 15-17 January 2009; San Francisco, Alexandria: American Society of Clinical Oncology.
15. Moehler M, Trarbach T, Seufferlein T, et al. Cetuximab with irinotecan/ Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results ofa nonrandomised multicentre AIO phase IIstudy[abstract#102]. In: American Society of Clinical Oncology GI Cancer Symposium 2008; 15-17 January 2008; San Francisco, Alexandria: American Society of Clinical Oncology.
16. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18:510-517. This is the first fully published phase II study of any combination of chemotherapy with cetuximab in first-line therapy in patients with advanced gastric cancer.
17. Schonnemann KR, Bjerregaard JK, Jensen HA, et al. Biweekly cetuximab and irinotecan as second-line therapy to patients with platinum-resistant gastro- esophageal cancer [abstract #73]. In: American Society of Clinical Oncology GI Cancer Symposium 2009; 15-17 January 2009; San Francisco, Alexandria: American Society of Clinical Oncology.
18. Pinto C, Di Fabio F, Barone C, et al. Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II Docetux study) [abstract #4575]. In: American Society of Clinical Oncology Annual Meeting 2008; 30 May-3 June 2008; Chicago, Alexandria: American Society of Clinical Oncology; 2008.
19. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
20. Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008; 99:868-874.
21. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591.
22. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77:858-863.
23. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna. J Clin Oncol 2006; 24:5201-5206.
24. Jhawer M. Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma [abstract#10]. In: American SocietyofClinical OncologyGI Cancer Symposium 2009; 15-17 January 2009; San Francisco, Alexandria: American Society of Clinical Oncology.
25. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277 -2285.
26. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232 -1239.
27. Moehler M., Hartmann J, Lordick F, et al. Sunitinib in patients with chemorefractory metastatic gastric cancer: preliminary results of an open-label, prospective nonrandomised multicentre AIO phase II trial [abstract #61]. In: American Society of Clinical Oncology GI Cancer Symposium2009; 15-17 January 2009; San Francisco, Alexandria: American Society of Clinical Oncology.
28. Bang Y, Kang Y, Kang W, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study [abstract #4603]. In: American Society ofClinical Oncology Annual Meeting 2007; 1-5 June 2007; Chicago, Alexandria: American Society of Clinical Oncology; 2007.
29. Sun W, Powell ME, O'Dwyer RH, et al. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adeno- carcinoma (ECOG 5303) [abstract #4535]. In: American Society of Clinical Oncology Annual Meeting 2008; 30 May-3 June 2008; Chicago, Alexandria: American Society of Clinical Oncology; 2008.
30. Parsons S, Murawa PX, Kolesnik OO, et al. Treatment of epitheloid cancer patients with malignant ascites using catumaxomab: results ofthe nonovarian stratum ofa phase II/III study [abstract#102]. In: American Society ofClinical OncologyGI Cancer Symposium 2008; 15-17 January 2008; San Francisco, Alexandria: American Society of Clinical Oncology; 2008.
31. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009; 45:275-280.